As the capstone in a multi-year transformation process, on May 9th, our parent company unveiled its new name and brand – Revvity.
For more than five years, EUROIMMUN has been part of PerkinElmer, Inc., which completed a divestiture of its applied, food and enterprise services businesses in March 2023. The remaining diagnostics and life science divisions of the Company, including EUROIMMUN, are now part of Revvity.
The name “Revvity” combines the two words “revolutionize” and “vita” (Latin for “life”), reflecting the Company’s purpose to expand the boundaries of human potential through science. As a trusted scientific solutions company Revvity aims to revolutionize next-generation breakthroughs that solve the greatest health challenges of humankind.
‟We’re a translational company in the sense that our capabilities facilitate decision making between research and clinical customers,” said Prahlad Singh, president and chief executive officer of Revvity. “With cross-business collaborations between our automation, multi-omics offerings, and our Signals software business, we have unique capabilities which put us in an optimal position to accelerate breakthrough solutions – starting with preclinical research and scientific discovery, all the way through to diagnosing and helping to treat disease.”
As one of the Company’s key franchises, the EUROIMMUN name will not disappear with the birth of Revvity. As a recognized leader in the diagnostics industry, EUROIMMUN’s trusted brand and unique product lines will live on for customers, partners and other stakeholders worldwide.
“We are overwhelmed by the rousing launch and branding of Revvity and proud to be a part of it. Within the new Company, EUROIMMUN represents an important cornerstone of the diagnostics division – a position that we will continue to strengthen together in the future through continuous development,” explains EUROIMMUN CEO Dirk Beecker.